Voronoi, capital increase of 45 billion paid in… New drug development speed battle – deal site
[딜사이트 강동원 기자] Voronoi, a company specializing in targeted therapies, has decided on a paid-up capital increase of 45 billion won. This is to expand its own global clinical trials for VRN11, a non-small cell lung cancer treatment currently in development. To enhance shareholder value, Voronoi CEO Kim Hyun-tae will invest 18 billion won in […]